Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Tissue Adhesive Versus Figure-of-Eight Suture for Femoral Venous Closure After Electrophysiology Procedures (GLUE-EP) (GLUE-EP)

3. November 2026 aktualisiert von: Otakar Jiravsky, Nemocnice AGEL Trinec-Podlesi a.s.

Topical Cyanoacrylate Tissue Adhesive Versus Figure-of-Eight Suture for Closure of Femoral Venous Access After Electrophysiology Procedures, Including Large-Bore Pulsed-Field Ablation: a Single-Centre Retrospective Cohort Study With Prospective Continuation (GLUE-EP)

In July 2026 the electrophysiology laboratory of a Czech tertiary cardiology centre introduced topical cyanoacrylate tissue adhesive (DERMABOND Mini or Histoacryl) as a routine alternative to the figure-of-eight suture for closing femoral venous puncture sites after electrophysiology procedures, including pulsed-field ablation performed through 13-17 F sheaths. After sheath removal, haemostasis is achieved by manual compression and the adhesive seals the skin over the puncture. The change was a clinical decision of the department, not a study intervention.

Published experience with this approach is limited, particularly for large-bore venous sheaths. GLUE-EP evaluates the access-site safety of the practice change using routinely recorded data only. Procedures closed with tissue adhesive are compared with a historical cohort closed with a figure-of-eight suture in 2024-2025 (propensity-score matched) and with a concurrent cohort closed with a suture during the same period. A prospective continuation collects the same routine data until 30 June 2027 from patients who give written informed consent.

The study assigns no treatment, adds no examination, questionnaire or study visit, and does not influence how the puncture site is closed. The primary outcome is any major or minor access-site vascular complication within 30 days of the procedure.

Studienübersicht

Detaillierte Beschreibung

BACKGROUND

Closure of the femoral venous puncture site is the most frequent source of complications after electrophysiology (EP) procedures. The departmental standard has been a percutaneous figure-of-eight suture, removed 2 to 6 hours after the procedure. Topical cyanoacrylate tissue adhesive is an alternative that requires no removal: after sheath removal, haemostasis is achieved by manual compression and the adhesive then seals the skin over the puncture, which is the use for which the CE-marked products are intended. With the spread of pulsed-field ablation, venous sheath size has increased to 13-17 F, so the question of closure is most pressing for large-bore access. Published experience is limited: the only comparative report identified in PubMed concerns skin adhesive combined with a vascular closure device after atrial fibrillation ablation, not adhesive used instead of a suture.

PRACTICE CHANGE

Since 1 July 2026 the EP laboratory of Nemocnice AGEL Trinec-Podlesi a.s. (Czechia) has used topical cyanoacrylate tissue adhesive (2-octyl cyanoacrylate, DERMABOND Mini; or n-butyl-2-cyanoacrylate, Histoacryl) as a standard alternative to the figure-of-eight suture. This was a clinical decision of the department, not a research intervention. By 17 September 2026, 192 procedures had been closed with adhesive (177 catheter ablations and 15 diagnostic EP studies; 127 pulsed-field ablations through 13-17 F sheaths). Adhesive was used in 40%, 73% and 72% of procedures in July, August and September 2026, respectively.

DESIGN

Single-centre observational cohort study in two parts with identical population and outcome definitions. The study does not assign the closure method; it is chosen by the treating physician.

Part R (retrospective):

  • Group A: procedures closed with adhesive from 1 July 2026 to the date of the ethics committee opinion (data cut-off 30 September 2026 for the first analysis).
  • Group B: procedures closed with a figure-of-eight suture from 1 January 2024 to 31 December 2025 (historical comparator).
  • Group C: procedures of the same period as Group A closed with a figure-of-eight suture (concurrent comparator).

Part P (prospective continuation): procedures closed with adhesive from the day after the ethics committee opinion to 30 June 2027, in patients who gave written informed consent before the procedure. Consent is sought at admission from all patients scheduled for an elective EP procedure with femoral venous access, because the closure method is decided during the procedure; only patients whose puncture site is closed with adhesive enter the analysis. The same routine variables are collected from the same sources; apart from obtaining consent, there is no additional examination, measurement, questionnaire or patient contact.

ASCERTAINMENT OF THE CLOSURE METHOD

In 2026, adhesive use is recorded in the departmental procedure registry. For Groups B and C, the closure method is taken from the procedure report and discharge summary. Because the figure-of-eight suture was the departmental standard, a procedure is classified as suture-closed unless another method is documented; procedures with another documented method (compression alone, vascular closure device) are excluded. The proportion of procedures without an explicit record of the suture is reported, and a sensitivity analysis restricts Groups B and C to procedures with an explicit record.

ASCERTAINMENT OF OUTCOMES

Access-site complications are identified from discharge summaries and from all records in the hospital information system up to day 30 after the procedure (outpatient visits, emergency department visits, readmissions, telephone contacts), not from the complication field of the departmental registry. A procedure without any record after discharge is counted as having no recorded complication; the proportion of such procedures is reported by group, and these procedures are excluded in a sensitivity analysis.

STATISTICAL ANALYSIS

Groups A and B are matched 1:1 by propensity score (nearest neighbour without replacement, caliper 0.2 SD of the logit of the score, exact matching on sheath size 5-9 F versus 13-17 F). The score is estimated by logistic regression from age, sex, procedure type, ablation system, number and size of sheaths, antithrombotic therapy and ultrasound-guided puncture; balance is checked by standardised differences (target below 0.1). The primary comparison (Group A versus matched Group B) uses the McNemar test and conditional logistic regression (odds ratio with 95% confidence interval). The comparison with Group C uses covariate-adjusted logistic regression, with inverse probability weighting as a sensitivity analysis. Binary secondary outcomes are analysed by logistic regression and length of stay (nights) by negative binomial regression. Part P is analysed descriptively and compared with Group A, with complication and conversion rates shown by calendar quarter. The large-bore (13-17 F) subgroup is pre-specified and analysed descriptively.

There is no formal sample size calculation; all eligible procedures in the defined periods are included. The study is estimation-oriented and is not designed to demonstrate non-inferiority. With 192 adhesive procedures, 0, 2 and 4 observed events correspond to upper limits of the 95% Wilson confidence interval of 2.0%, 3.7% and 5.2%, respectively.

Not collected: time to haemostasis, time to ambulation, pain scores, patient satisfaction, closure cost and operator confidence. These are not recorded in routine documentation and will not be reported.

ETHICS AND DATA PROTECTION

The protocol was submitted to the Ethics Committee of Nemocnice AGEL Trinec-Podlesi a.s. in October 2026, with a request for waiver of informed consent for Groups A, B and C; written informed consent is obtained in Part P. The analytic dataset is pseudonymised; the key is held on a secure hospital server and is accessible only to the principal investigator. Only aggregate data are reported.

DISSEMINATION

Abstract at an international cardiology congress and publication in a peer-reviewed journal regardless of the direction of the results.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1400

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Třinec, Tschechien, 73961
        • Nemocnice AGEL Trinec-Podlesi a.s.
        • Kontakt:
        • Hauptermittler:
          • Otakar Jiravsky, MUDr., Ph.D., MBA
        • Unterermittler:
          • Bogdan Szmek, MUDr.
        • Unterermittler:
          • Jan Chovancik, MUDr., Ph.D., MBA
        • Unterermittler:
          • Radek Jancar, MUDr.
        • Unterermittler:
          • Ivan Ranic, MUDr., MBA
        • Unterermittler:
          • Jan Adamek, MUDr.
        • Unterermittler:
          • Martina Hrosova, MUDr.

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adults undergoing elective electrophysiology procedures (diagnostic EP studies and catheter ablations, including pulsed-field ablation) with femoral venous access at the electrophysiology laboratory of Nemocnice AGEL Trinec-Podlesi a.s., Czechia, identified consecutively from the departmental procedure registry within the defined periods.

Beschreibung

Inclusion Criteria:

  • Age 18 years or older
  • Elective electrophysiology procedure (diagnostic study or catheter ablation) with at least one femoral venous sheath
  • Femoral venous puncture site closed with topical cyanoacrylate tissue adhesive (Groups A and P) or with a figure-of-eight suture (Groups B and C)
  • Group P only: written informed consent to the use of routine medical records

Exclusion Criteria:

  • Arterial access during the same procedure
  • Non-elective or emergency procedure
  • Groups B and C: documentation of a closure method other than a figure-of-eight suture (compression alone, vascular closure device)
  • Group P only: inability to understand the patient information or to give consent

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: OTHER

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Group A: Tissue adhesive (retrospective)

Elective EP procedures with femoral venous puncture sites closed with topical cyanoacrylate tissue adhesive from 1 July 2026 to the date of the ethics committee opinion. Data from routine records; waiver of consent requested.

Routine clinical practice, not assigned by the study. After sheath removal and haemostasis by manual compression, the skin over the femoral venous puncture is sealed with CE-marked topical cyanoacrylate tissue adhesive: 2-octyl cyanoacrylate (DERMABOND Mini) or n-butyl-2-cyanoacrylate (Histoacryl).

Andere Namen:
  • DERMABOND Mini
  • Histoacryl
Group B: Figure-of-eight suture (historical)

Elective EP procedures closed with a percutaneous figure-of-eight suture from 1 January 2024 to 31 December 2025; propensity-score matched 1:1 to Group A. Data from routine records; waiver of consent requested.

Routine clinical practice, not assigned by the study. Percutaneous figure-of-eight (purse-string) skin suture placed over the femoral venous puncture after sheath removal and released 2 to 6 hours later.

Group C: Figure-of-eight suture (concurrent)

Elective EP procedures of the same period as Group A (from 1 July 2026 to the date of the ethics committee opinion) in which adhesive was not used and the puncture site was closed with a figure-of-eight suture. Data from routine records; waiver of consent requested.

Routine clinical practice, not assigned by the study. Percutaneous figure-of-eight (purse-string) skin suture placed over the femoral venous puncture after sheath removal and released 2 to 6 hours later.

Group P: Tissue adhesive (prospective continuation)

Elective EP procedures closed with topical cyanoacrylate tissue adhesive from the day after the ethics committee opinion to 30 June 2027, in patients who gave written informed consent before the procedure. Same routine variables and sources as Group A.

Routine clinical practice, not assigned by the study. After sheath removal and haemostasis by manual compression, the skin over the femoral venous puncture is sealed with CE-marked topical cyanoacrylate tissue adhesive: 2-octyl cyanoacrylate (DERMABOND Mini) or n-butyl-2-cyanoacrylate (Histoacryl).

Andere Namen:
  • DERMABOND Mini
  • Histoacryl

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants With Access-Site Vascular Complications
Zeitfenster: From the procedure through 30 days after the procedure

Any major or minor vascular complication at the femoral venous access site, using VARC-3 criteria adapted for venous access. Major: bleeding requiring transfusion or surgical or interventional revision; pseudoaneurysm or arteriovenous fistula requiring treatment; access-site infection requiring systemic antibiotics or revision; deep vein thrombosis. Minor: haematoma without transfusion or revision but with prolonged hospital stay or unplanned healthcare contact; pseudoaneurysm or fistula managed conservatively; local reaction requiring treatment. Ascertained from discharge summaries and all hospital records up to day 30. Primary comparison: Group A versus propensity-matched Group B; key secondary comparison: Group A versus Group C. Pre-specified subgroup: 13-17 F sheaths.

From the procedure through 30 days after the procedure

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants Requiring Conversion From Tissue Adhesive to Figure-of-Eight Suture
Zeitfenster: During the index procedure (day 0)

Conversion to a figure-of-eight suture because of inadequate haemostasis immediately after sheath removal, in procedures intended for adhesive closure (Groups A and P). Ascertained from the procedure report and discharge summary.

During the index procedure (day 0)
Number of Participants Discharged on the Day of the Procedure
Zeitfenster: Day 0 (day of the procedure)

Discharge from hospital on the calendar day of the index procedure, as recorded in the departmental registry.

Day 0 (day of the procedure)
Length of Post-Procedural Hospital Stay
Zeitfenster: From the procedure to hospital discharge, assessed up to 30 days

Number of nights spent in hospital after the index procedure, taken from the discharge summary.

From the procedure to hospital discharge, assessed up to 30 days
Number of Participants With Unplanned Healthcare Contact Related to the Access Site
Zeitfenster: From discharge through 30 days after the procedure

Any unplanned outpatient visit, emergency department visit, readmission or telephone contact related to the femoral access site, as recorded in the hospital information system.

From discharge through 30 days after the procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Otakar Jiravsky, MUDr., Ph.D., MBA, Nemocnice AGEL Trinec-Podlesi a.s.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. Juli 2027

Studienabschluss (Geschätzt)

1. September 2027

Studienanmeldedaten

Zuerst eingereicht

3. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. November 2026

Zuerst gepostet (Tatsächlich)

9. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Only aggregate results will be published. Individual participant data will not be shared: the retrospective part relies on a waiver of consent, and participants in the prospective part consent to the use of their pseudonymised data by the study team only.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren